2Satehler M, Haseke N, Schoppler G, et al. therapy strategies for advanced renal cell carcinoma [J]. Urolage A,2006,45(1) :99-112.
3Samlowski WE, Vogelzang NJ. Emerging drug for treatment of metastatic renal cancer [J]. Expert Opin Emerg Drugs,2007,14(4):605-618.
4Wysocki P J, Zolnierek J, Szczylik C, et aI. Targeted therapy of renal cell cancer [J]. Curr Opin Investig Drugs,2008,9(6) :570-575.
5Coppin C, Le L, Porzsolt F, et al. Targeted therapy for advanced renal cell carcinoma [J]. Cochrone Database Syst Rev, 2008,2 :CD006017.
6Hilles JJ,Kolessar JM. Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma [J]. Am J Heath Syst Pharm,2008,65(2):123-131.
7Motzer RJ,Rini BI,Bukowiski RM,et al. Sunitinib in patients with metastatic renal carcinoma [J]. JAMA, 2006,295(21) :2516-2524.
8Motzer R J, Michaelson MD, Rosenberg J, et al. Sunitinib efficacy against advanced renal cell carcinoma [J]. J Urol 2007,18 (5) : 1883-1887.
9Motzer R J, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal cell carcinoma [J]. N Engl J Med, 2007, 356 (2) :115 -124.
10Reddy K, Phase Ⅲ study of sunitinib malate (SU 11248) versus interferon-alpha as first-line treatment in patient with metastatic reeal cell carcinoma [J]. Clin Genitourin Cancer, 2006,5 (1) : 23 - 25.
二级参考文献19
1De Jonge M I A,Verweij J.Multiple targeted tyrosine kinase inhibition in the clinic:All for one or one for all?[J].Eur J Cancer,2006,42(10):1351-1356.
8Motzer R J,Michaelson M D,Redman B G,et al.Activity of SU 11248 a multitargeted inhibitor of vascular endothelial growth factor and platelet-derived growth factor receptor,in patients with metastatic renal cell carcinoma[J].J Clin Oncol,2006,24(11):16-24.
9Faivre S,Dalbalao C,Vera K,et al.Safety pharmacokinetic,and antitumor activity of SU 11248,a novel oral multitarget tyrosine kinase inhibitor,in patients with cancer[J].J Clin Oncel,2006,24(1):25-35.
10Motzer R J,Rini B I,Bukowiski R M,et al.Sunitinib in patients with metastatic renal carcinoma[J].JAMA,2006,295(21):2516-2524.
4Fernando NT,Koch M,Rothrock C,et al.Tumor escapefrom endogenous,extracellular matrix-associatedangiogenesis inhibitors by up-regulation of multipleproangiogenic factors[J].Clin Cancer Res,2008,14(5):1529-1539.
5Shi Y,Yan H,Frost P,et al.Mammalian target ofrapamycin inhibitors activate the AKT kinase in multiplemyeloma cells by up-regulating the insulin-like growthfactor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade[J].Mol CancerTher,2005,4(10):1533-1540.
6Escudier B,Roigas J,Gillessen S,et al.Phase II study ofsunitinib administered in a continuous once-daily dosingregimen in patients with cytokine-refractory metastaticrenal cell carcinoma[J].J Clin Oncol,2009,27(25):4068-4075.
7Motzer RJ,Hutson TE,Olsen MR.Randomized phase IImulticenter study of the efficacy and safety of sunitinibon the 4/2 versus continuous dosing schedule as first-line therapy of metastatic renal cell carcinoma:RenalEFFECT Trial[J].J Clin Oncol,2011,29(suppl 7):abstr LBA308.
8Zhang L,Bhasin M,Schor-Bardach R,et al.Resistanceof renal cell carcinoma to sorafenib is mediated bypotentially reversible gene expression[J].PLoS One,2011,6(4):e19144.
9Ratain MJ,Eisen T,Stadler WM,et al.Phase II placebo-controlled randomized discontinuation trial of sorafenibin patients with metastatic renal cell carcinoma[J].JClin Oncol,2006,24(16):2505-2512.
10Hong D,Gordon M,Appleman L,et al.Interim resultsfrom a phase 1b study of safety,pharmacokinetics andtumor response of the angiopoietin1/2-neutralizingpeptibody AMG 386 in combination with AMG 706(motesanib),bevacizumab or sorafenib in advancedsolid tumors[J].Ann Oncol,2008,19:viii154,(abstr462PD).